semaglutide mash GLP-1 BREAKTHROUGH: FDA APPROVES TREATMENT FOR SERIOUS LIVER DISEASE Semaglutide, a medication already known for its role in weight management, is now the first GLP-1 therapy approved to treat (Metabolic Dysfunction–Associated Semaglutide's Efficacy in Phase 3

The goal isn't to feel miserable

Some patients describe feeling "wired but tired," a state where the body feels energized but the mind feels frayed

These findings have led to NICE recommendations supporting the use of certain GLP-1 receptor agonists in patients with type 2 diabetes and established cardiovascular disease or at high cardiovascular risk

Importantly, the vast majority of the available PCOS models are generated by exogenous administration of androgens during specific developmental windows, which hampers evaluation of the effects of treatments on endogenous androgen secretion and ovarian function

All research referenced in this article was conducted in animal models or in vitro systems

The IP and development strategies of leading players reflect this broader therapeutic ambition